Skip to main content
Top

03-21-2018 | DPP-4 inhibitors | Highlight | News

DPP-4 inhibitor use linked to inflammatory bowel disease risk

print
PRINT
insite
SEARCH

medwireNews: Researchers have detected a possible increased risk for inflammatory bowel disease (IBD) among users of dipeptidyl peptidase (DPP)-4 inhibitors.

The overall risk was small, however. According to the team’s calculations, 2291 patients would need to take DPP-4 inhibitors for 2 years (or 1177 for 4 years) before one excess case of IBD would be diagnosed.

“Although the absolute risk is low, physicians should be aware of this possible association and perhaps refrain from prescribing dipeptidyl peptidase-4 inhibitors for people at high risk (that is, those with a family history of disease or with known autoimmune conditions),” write Laurent Azoulay, from Jewish General Hospital in Montreal, Quebec, Canada, and study co-authors in The BMJ.

The incidence rate of IBD was 53.4 per 100,000 person–years among 7231 patients, identified in the UK’s Clinical Practice Research Datalink, who were taking a DPP-4 inhibitor.

The corresponding rate among 133,939 patients taking other non-insulin antidiabetic medications was 34.5 per 100,000 person–years. This amounted to a significant 75% increased risk associated with DPP-4 inhibitor use after allowing for a range of potential confounders including age, sex, diabetes duration and complications, use of nonsteroidal anti-inflammatory drugs, and the presence of other autoimmune conditions.

Patients using DPP-4 inhibitors who develop “persistent gastrointestinal symptoms such as abdominal pain or diarrhoea should be closely monitored for worsening of symptoms,” says the team.

The association persisted in a competing risk analysis, and in analyses including those that accounted for a 1-year exposure lag period, were restricted to clinically supported events, and were stratified by age. There did not appear to be a specific DPP-4 inhibitor driving the association, but the researchers caution that the numbers of events were too low to be certain.

The highest rates of IBD diagnosis occurred between 2 and 4 years after first DPP-4 inhibitor prescription and between 3 and 4 years of their use, at a respective 74.1 and 83.1 per 100,000 person–years.

“This gradual increase in the risk is consistent with the hypothesis of a possible delayed effect of the use of dipeptidyl peptidase-4 inhibitors on the incidence of inflammatory bowel disease,” say Azoulay and colleagues.

By Eleanor McDermid

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »